Slynd Kit
NDC Package 0642-7470-01
Package Information
Slynd (drospirenone) kits is a medication used to prevent pregnancy. This formulation utilizes a kit delivery system. Marketed by Exeltis Usa, Inc., this product is identified by NDC 0642-7470 and is authorized under FDA application NDA211367.
Identification & Billing
- RxCUI: 2171000 - drospirenone 4 MG Oral Tablet
- RxCUI: 2171001 - {24 (drospirenone 4 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack
- RxCUI: 2171001 - drospirenone 4 MG (24) Oral Tablet / Inert Ingredients 1 MG (4) Oral Tablet 28 Day Pack
- RxCUI: 2171002 - {24 (drospirenone 4 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack [Slynd]
- RxCUI: 2171002 - Slynd 28 Day Pack
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0642 - Exeltis Usa, Inc.
- 0642-7470 - Slynd
- 0642-7470-01 - 1 KIT in 1 CARTON * 24 TABLET, FILM COATED in 1 BLISTER PACK * 4 TABLET, FILM COATED in 1 BLISTER PACK
- 0642-7470 - Slynd
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0642-7470). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0642-7470-01 identifies a specific commercial package of 1 kit in 1 carton * 24 tablet, film coated in 1 blister pack * 4 tablet, film coated in 1 blister pack of Slynd, a human prescription drug labeled by Exeltis Usa, Inc.. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Exeltis Usa, Inc. on June 06, 2019. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to prevent pregnancy. Drospirenone (a progestin) is a hormone that works mainly by preventing the release of an egg (ovulation) during your menstrual cycle. It also makes vaginal fluid thicker to help prevent sperm from reaching an egg (fertilization) and changes the lining of the uterus (womb) to prevent attachment of a fertilized egg. Besides preventing pregnancy, birth control pills may make your periods more regular, decrease blood loss and painful periods, and decrease your risk of ovarian cysts. Using this product does not protect you or your partner against sexually transmitted diseases (such as HIV, hepatitis B, gonorrhea, syphilis). To decrease your risk of infection, always use an effective barrier method (latex or polyurethane condom/dental dams) during all sexual activity.
How is this Exeltis Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00642747001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
